Abstract. The p53 protein is one of the best-known tumor suppressors. Recently discovered ASPP1 and ASPP2 are specific activators and iASPP is an inhibitor of p53. In the present study, we found that of 37 NSCLC patients, p53 alterations were detected in 20 tumors (54.1%), the mRNA expression of ASPP1 and ASPP2 was frequently dowregulated in tumor tissues, and this decreased significantly in samples expressing wild-type p53. The expression of ASPP1 and ASPP2 was downregulated and that of iASPP was upregulated in two NSCLC cell lines (the NCI-H157 cell line with altered p53 and the A549 cell line with wild-type p53). The NCI-H157 cell with higher ASPP1 and ASPP2 levels was more sensitive to cisplatin than the A549 cells with lower ASPP1 and ASPP2 levels. Downregulation of iASPP by siRNA stimulated apoptosis through p53 in two NSCLC cell lines. These findings provide new insights into the molecular mechanisms of action of the ASPP family in NSCLC and may have potent therapeutic applications.
Introduction
Lung cancer is divided into two morphological types, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Lung carcinoma is currently the leading cause of cancer mortality. Therefore, many investigators are studying the molecular and biologic characteristics of lung carcinoma in an attempt to develop effective targeted therapy.
The p53 protein is one of the best known tumor suppressor proteins, playing a key role in apoptosis, trigger cell cycle arrest (1) , and possessing high frequency of mutations in a wide range of human cancers. In some studies, approximately 50% of NSCLC carry the p53 gene alteration (2, 3) .
The apoptosis stimulating protein of p53 (ASPP) family consists of three proteins, ASPP1, ASPP2 and iASPP. ASPP1 and ASPP2 function as tumor-suppressor genes and have been reported to interact with p53 and specifically enhance p53-induced apoptosis, but not that of the cell cycle arrest (4, 5) . Subsequent studies further demonstrate that ASPP1 and ASPP2 can regulate apoptosis mediated by p63 and p73 and function as common activators of p53 family members (6) . The iASPP protein identified is a pro-oncogene, inhibits p53-mediated apoptosis (7, 8) , which implies that iASPP can compete with ASPP1 and ASPP2 for binding to p53, thereby inhibiting the ability of ASPP1 and ASPP2 to stimulate the apoptosis function of p53.
Altered expression of the ASPP family members has been found in a variety of human cancers. The expression of ASPP1 and ASPP2 is frequently downregulated in human breast carcinomas expressing wild-type p53 (4) , and in three tumor cell lines retaining wide-type p53 (9) . Higher expressions of iASPP were also detected in human breast carcinomas (7) . Reduced levels of ASPP2 have also been detected in colon cancer cell lines (10) , and ASPP1 downregulation was observed in two mesothelioma cell lines (11) . The level of ASPP1 is downregulated and that of the iASPP is upregulated in leukemia cell lines and acute leukemia tissues (12, 13) . The expression of ASPP1 and ASPP2 was diminished in seven hepatocellular carcinoma cell lines (14) .
Moreover, previous studies have shown downregulation of ASPP1 in NCI-H226 lung carcinoma cell line (11) and reduced levels of ASPP2 in lung carcinoma cell lines (10) . The expression of iASPP was significantly higher in lung cancer tissues compared with the normal tissues in lung cancer (15) . These results indicated that ASPP family may produce a marked effect in lung carcinoma. In this study we analyzed the correlation between the mRNA expression levels of ASPP1, ASPP2 and the status of p53 in human NSCLC samples, and the expression pattern of ASPP1, ASPP2 and iASPP in two human NSCLC cell lines (1 with wild-type p53 and 1 with altered p53). We also investigated the sensitivity of two NSCLC cell Cell lines and cell culture. The human non-small cell lung squamous carcinoma A549 cells and human non-small cell lung adencarcinoma NCI-H157 cells were obtained from the Cell Centre of School of Basic Medicine Peking Union Medical College (Beijing, China) and maintained in RPMI-1640 medium supplemented with 10% (v/v) fetal bovine serum (Hyclone). Two cell lines were incubated at 37˚C in a humidified atmosphere with 5% CO 2 .
RNA preparation, reverse transcription and quantitative realtime qPCR. Total RNA was extracted from A549, NCI-H157 cell lines and various tissue specimens using RNAiso reagent (Takara). The RNA was reverse-transcribed into cDNA with a PrimeScript II First Strand cDNA Synthesis kit (Takara). Quantitative real-time PCR was carried out in the LightCycle real-time PCR (Roche) using SYBR Premix Ex Taq™ kit for Perfect Real-Time (Takara). All the real-time PCR primers used are listed in Table I .
MTT assay and cell growth determination. Cell growth was measured by 3-(4,5)-dimethylthiazol(-2-y1)-3,5-diphenyltetrazolium bromide (MTT) assay (Sigma) following the instructions of the manufacturer. Cells were plated into 96-well plates and treated with 0.75, 1.5, 3.0, 6.0, 12.0 µg/ml of cisplatin. After 24 h, MTT reagent (5 µg/µl) was added (15 µl/well) and incubated at 37˚C for 4 h. The reaction was stopped with addition of 150 µl DMSO and the optical density was determined at OD 570 nm on a multi-well plate reader. Each sample was done in triplicate and repeated three times.
Protein preparation and western blotting. Total protein of A549 and NCI-H157 cells was extracted with RIPA lysis buffer (150 mM NaCl, 25 mM Tris-HCl pH 7.6, 1% NP-40, 1% sodium deoxycholate, 1% SDS and 1% protease inhibitor cocktail). The cells were harvested, washed and lysed in cold RIPA buffer.
Total proteins were resolved using 8% SDS-PAGE and transferred to an NC-membrane (Millipore, Darmstadt, Germany). Western blotting was performed according to standard protocols. To analyze ASPP family protein levels, we generated three monoclonal antibodies against the 120-kDa ASPP1 protein (1,090 amino acids), 126-kDa ASPP2 protein (1,128 amino acids) and 89-kDa iASPP protein (828 amino acids). The secondary antibody was goat anti-mouse IgG conjugated to horseradish peroxidase (1:3000, Pierce). Immunoblots were visualized on photographic film using the ECL kit (Pierce), following the method provided by the supplier. For the loading control, anti-β-actin monoclonal antibody (1:5000, Sigma) was used.
Detection of apoptosis. Cell morphology and apoptosis were analyzed by a transmission electron microscope. Trypsin digestion of cells from a single cell suspension, at low-speed centrifugation, and placement in ice-cold 15% glutaraldehyde and 1% osmium acid, then double-fix-embedded, cut to 70-nm thick sections. Toluidine staining was applied, light microscopy positioning, and transmission electron microscopy observation of cell ultrastructure followed.
RNA interference. RNA interference was performed by using the synthetic siRNA duplexes (Takara). Two synthetic siRNA duplexes (si1-iASPP and si2-iASPP) targeting iASPP cDNA sequences 5'-ACAGTACCAGCAGATCATC-3' and 5'-TTAC AAGGTCTCTCCCTCTG-3' were used to inhibit iASPP Statistical analysis. The analyses were carried out using SPSS 13.0 for Windows software. Data are presented as mean ± SD, and comparison between the two groups used single factor analysis of variance. A P<0.05 was considered statistically significant.
Results
Comparative analysis of the ASPP family. The human ASPP family is composed of three proteins, ASPP1, ASPP2 and iASPP. iASPP protein identified is by far the most evolutionary conserved member of ASPP family, and the only member identified in Caenorhabditis elegans (7) . Mammals, including mice and humans, have evolved two additional members, ASPP1 and ASPP2 (4). Three proteins share structure similarity in C-termini which contains their signature sequence of Ankyin repeats and SH3 domain (Fig. 1A) . Study confirmed that the ASPP family members bind the core domain of p53 through Ankyin repeats and SH3 domain. ASPPl is a l,090-amino acid protein, encoded by gene PPPIRl3B, and ASPP2 consists of 1,128 amino acids, encoded by p53BP2 gene. In human, PPPIR13L gene encodes the iASPP, complete iASPP composed of 828 amino acids. Protein sequence analysis showed 47.5% similarity between ASPP1 and ASPP2 protein (Table ⅠI) . Gene PPPIRl3B, p53BP2 and PPPIR13L is located in 14q32.33, 1q41, 19q13.32 chromatin, respectively. The cDNAs of PPPIRl3B and p53BP2 are 4,976 bp and 4,802 bp long, respectively, with each consisting of 17 exons and the other consisting of 19 exons. PPPI R13L cDNA has a full length of 3,122 bp and consists of 13 exons (Fig. 1B) . Sequence analysis revealed that the ASPP1 and ASPP2 mRNA sequences share similarity with iASPP (>40%), ASPP1 and ASPP2 with higher similarity (>50%) (Table II) , ASPP1 is the homology analogues of ASPP2.
Expression of mut-p53 protein and ASPP1, ASPP2 mRNA in NSCLC tissues and correlation of the expression of ASPP1, ASPP2 with the development of NSCLC. To investigate the possible connection between ASPP1, ASPP2 and p53 in human NSCLC, we first analyzed the expression of the mut-p53 protein in cancer tissues and normal lung tissues by carrying out immunohistochemical staining. Mut-p53 protein located in the nucleus, the nuclei appeared brown for the positive expression of mut-p53 ( Fig. 2A) . We found that in 20 out of 37 patient cancer tissues (54.1%) showed mut-p53 protein positivity, of which adenocarcinoma in 9 patients, squamous cell carcinoma in 10 patients and giant cell carcinoma 1 patient, the mut-p53 expression between adenocarcinoma and squamous cell carcinoma was not significantly different (P>0.05). Normal lung tissues in 2 patients were positive for mut-p53 protein, the positive rate was 5.4% (Fig. 2B) .
To confirm the expression of ASPP1 and ASPP2 mRNAs, we carried out real-time qPCR. In cancer, paracarcinomatous and normal lung tissues, the expression of ASPP1 and ASPP2 mRNA showed a gradual increasing trend. The mRNA levels of ASPP1 and ASPP2 in cancer tissues was lower than the paracarcinomatous and normal lung tissues (P<0.05) (Fig. 2C) . We also analyzed the mRNA expression of ASPP1 and ASPP2 between mut-p53 positive group and mut-p53-negative group. We found that the ASPP1 and ASPP2 mRNA levels were lower in mut-p53-negative cancer tissues than in mut-p53-positive cancer tissues (P<0.05) (Fig. 2D) , demonstrating that human NSLC in expression of wild-type p53 protein may be associated with the decreased mRNA levels of ASPP1 and ASPP2. . Analysis showed that the mRNA level of ASPP1 and ASPP2 was downregulated and that of the iASPP was upregulated in two cell lines, and specifically showed remarkably low expression of ASPP1, and ASPP2, but relatively high expression of iASPP in A549 cell (Fig. 3A) . The protein expression of ASPP1 and ASPP2 was fewer than iASPP in A549 cell, coinciding with their mRNA expressions. In NCI-H157 cell, there was no significant difference in protein expression among these three proteins (Fig. 3B) .
To explore the regulation action of ASPP family in NSCLC cells, we treated cells with cisplatin and evaluated the cell viability, the changes in ASPP1, ASPP2 and iASPP mRNA and protein levels, and apoptosis.
We used the MTT assay to evaluate the growth inhibitory effect of cisplatin on A549 and NCI-H157 cell lines and calculated the IC50 values. Cisplatin inhibited cell growth in a concentration-dependent manner in two cell lines. The IC50 value for the A549 cells was 10.5 µg/ml and for NCI-H157 cell was 3.7 µg/ml (Fig. 3C) . As demonstrated in Fig. 3C , the NCI-H157 cell line expressing high levels of ASPP1 and ASPP2 showed higher sensitivity to cisplatin.
The expression of ASPP1, and ASPP2 was significantly increased at the RNA and protein level after cisplatin treatment, whereas the expression of iASPP was only slightly decreased in A549 and NCI-H157 cell ( Fig. 3D and E) .
To confirm that cisplatin caused apoptosis, we observed cell morphology by a transmission electron microscope before and after cisplatin treatment. After cisplatin treatment organelle swelling was seen, as well as membrane retraction, irregular shrinkage, apoptotic cell appearance, and chromatin gathering under the nuclear membrane or crescent-shaped distribution (Fig. 3F) .
Regulatory function on apoptosis by iASPP in NSCLC cell lines.
To investigate the effects of iASPP on apoptosis, two transcript-specific small interfering RNAs (siRNAs) specifically targeting exon 7 of iASPP (si1-iASPP) and exon 8 of iASPP (si2-iASPP) against iASPP were designed and transfected into NSCLC cells (Fig. 4A) . The mRNA and protein levels of iASPP were initially characterized after knockdown by si1-iASPP and si2-iASPP in A549 and NCI-H157 cell lines. The results indicated that the si1-iASPP and si2-iASPP both caused visible reductions in iASPP mRNA and protein levels ( Fig. 4B and C) . The si1-iASPP and si2-iASPP oligonucleotides were designed to target the sequences which do not overlap with ASPP1, and ASPP2, to avoid cross silencing.
We examined the cell morphology and cell count using transmission electron microscopy before and after the si1-iASPP and si2-iASPP treatment. The ratio of apoptotic to total cells was measured to analyze the apoptosis level. After the knockdown of iASPP, apoptotic cells were seen, the apoptosis rates were remarkably increased (Fig. 4D ) in the two cell lines, suggesting that high expression of iASPP may inhibit apoptosis in NSLC cell lines.
Discussion
Our study in 37 NSCLC samples (20 of these samples express mutant p53 while the other 17 express wild-type p53) showed that the mRNA expression of ASPP1 and ASPP2 in lung tumor tissues was lower than in normal lung tissues. Thus, it was indicated that the downregulation of ASPP might be a characteristic of NSCLC tumors. Moreover, we also found the expression levels of ASPP1, and ASPP2 in tumor tissues with wild-type p53 was lower than that with mutant p53, suggested that the decreased expression of ASPP1 and ASPP2 caused the wild-type p53 to fail its role as a tumor suppressor in NSCLC.
We found that the level of ASPP1 and ASPP2 was downregulated and that of the iASPP was upregulated in two NSCLC cell lines with different genetic background, A549 cell line expressed wild-type p53 and NCI-H157 cell line expressed mutant p53.
Our results suggested ASPP family expression level was not associated with the p53 status in the two NSCLC cell lines, abnormal ASPP family expression could be an important step in the formation of human lung neoplasms and might be a useful molecular marker for the diagnosis of NSCLC.
The present study is the first report of downregulation of ASPP1 and ASPP2 in tumor tissues and a cell line and upregulation of iASPP in a tumor cell line with mutant p53.
We thus examined the sensitivity of these two cell lines to the DNA-damaging agent cisplatin and found that two cell lines were sensitive to cisplatin. The NCI-H157 cell line with high expression level of ASPP1, ASPP2 showed higher sensitivity for cisplatin. Upon treatment with cisplatin, the expression of ASPP1, and ASPP2 at mRNA and protein levels were significantly increased, whereas the expression of iASPP was only slightly decreased in the two cell lines. These observations suggested a possibility that expression of ASPP1 and ASPP2 might be correlated with the sensitivity to the DNA damaging agent. In A549 cell line with wild-type p53, upregulation of ASPP1 and ASPP2 expression by cisplatin should enhance the apoptotic function of p53 and profit tumor therapy. However, in NCI-H157 cell lines with mutant p53, the functions of upregulated ASPP1 and ASPP2 expression are unknown and need further study.
In the present study, we also demonstrated that iASPP is overexpressed in two human NSCLC cell lines, and siRNA mediated downregulation of iASPP results in stimulation of apoptotic function of p53. The function on apoptosis by iASPP was more significant in the A549 cell line, suggesting iASPP plays important roles in NSCLC and maybe a target for lung cancer therapy associated with the p53 pathway.
